Skip to main content

Translational Glycobiology in Human Health and Disease

  • 1st Edition - November 29, 2023
  • Latest edition
  • Editors: Michelle Kilcoyne, Lokesh Joshi
  • Language: English

Along with nucleic acids, proteins, and lipids, carbohydrates stand as one of four main components of cellular architecture. However, glycobiology (or carbohydrate bioscience) is… Read more

World Book Day celebration

Where learning shapes lives

Up to 25% off trusted resources that support research, study, and discovery.

Description

Along with nucleic acids, proteins, and lipids, carbohydrates stand as one of four main components of cellular architecture. However, glycobiology (or carbohydrate bioscience) is little understood by non-experts, partly because carbohydrates are a complex, diverse class of molecules structurally and functionally. In recent years, advances in computational analytics (glycomics) have allowed us to better interpret and realize the importance of glycobiology in human health and disease, and glycans and their associated processes have been shown to play a significant role across a variety of disease types. As the biomedical sciences continue to adopt multi-omic and precision medicine approaches, a greater understanding of glycobiology is essential for maintaining healthy physiology and advancing disease treatment.

Translational Glycobiology in Human Health and Disease offers a deep examination of glycobiology for experts and non-experts alike in areas ranging from the role of glycobiology in chronic and infectious diseases to advances in technologies for higher throughput analysis and diagnosis. While keeping human health in the forefront, this book integrates a thorough discussion of glycobiology fundamentals with its growing areas of application and societal impact. With emphasis throughout on the interdisciplinary nature of glycosciences, this book also features perspectives from the health, computational (glycoanalytics), materials, biopharmaceutical, and diagnostic sciences.

Disease and speciality areas addressed include gycoimmunology, neuroglycobiology, commensal glycobiology, gut health, regenerative medicine and glycobiology, glycobiology and cancer, congenital disorders of glycosylation, infectious disease glycobiology, and parasite glycobiology. Computational approaches discussed, supporting the advance of new research, include advanced glycoanalytics, glycomics microarrays, glycoengineering, and glycol systems biology. Additionally, authors consider impact areas for society and public health, such as glycobiology and entrepreneurship, policy and regulatory requirements for glycosylation, future research, and translation to new diagnostics and drug discovery.

Key features

  • Provides a deep, foundational overview of glycoscience and its translational potential, highlighting glycobiology’s growing role in human health and disease study
  • Examines a broad range of relevant disease areas and applications of glycobiology in policy and public health
  • Features chapter contributions from leading, international experts in the field, fully integrating perspectives from the health, computational, materials, biopharmaceutical, and diagnostic sciences

Readership

Active researchers in biochemistry, molecular biology, nutrition, and cell biology, industrial scientists, biomedical engineers, nutritional scientists, pharmacologists, clinician scientists, medicinal chemists, analytical chemists

Table of contents

Section 1: Glycobiology

2. Carbohydrates and human glycosylation

3. Carbohydrate-binding proteins

4. Carbohydrate-active enzymes

Section 2: Glycobiology and health

5. Glycoimmunology

6. Neuroglycobiology

7. Commensal glycobiology and gut health

8. Microbiota accessible carbohydrates and the gut microbiome

9. Regenerative medicine and glycobiology

10. Exosome glycosylation for signalling and function

Section 3: Glycobiology and disease

11. Cancer

12. Altered glycosylation in autoimmune diseases

13. Metabolic diseases: Disorders of carbohydrate metabolism and lysosomal storage

14. Congenital Disorders of Glycosylation

15. Microbial infectious disease glycobiology

16. Parasite glycobiology

17. Glycobiology of neurodegenerative diseases

18. Glycobiology of neural injury and regeneration

Section 4: Glycotechnologies

19. Diagnostics and novel carbohydrate recognition molecules

20. Advanced glycoanalytics

21. Glycomics microarrays

22. Glycoengineering and systems biology

23. Computational Glycobiology

24. Carbohydrate-incorporated Biomaterials

Section 5: Glycobiology and Society

25. Translational glycobiology and entrepreneurship for health

26. Glycobiology: Public engagement and society

27. Policy and regulatory requirements for glycosylation

28. Public health and translational glycobiology

29. Future perspectives/ summary

Product details

  • Edition: 1
  • Latest edition
  • Published: November 29, 2023
  • Language: English

About the editors

MK

Michelle Kilcoyne

Dr. Michelle Kilcoyne is Lecturer in Glycosciences at the National University of Ireland Galway. Dr. Michelle Kilcoyne completed her PhD in analytical carbohydrate chemistry in the School of Chemistry at NUI Galway in 2004, specialising in structural analysis of bacterial polysaccharides. She then took up a postdoctoral position in Arizona State University where she further specialised in mass spectrometry and HPLC, as well as expanding her interests to mammalian glycosylation. She returned as a postdoctoral researcher to NUI Galway in 2007 working on industry-supported and European projects, developing high throughput platforms for carbohydrate profiling. In 2014 Dr. Kilcoyne was appointed Lecturer in Glycosciences, is currently a member of Discipline of Microbiology at NUI Galway and leads the Carbohydrate Signalling Group. She is the recipient of a Royal Society of Chemistry Analytical Chemistry Trust Fund Fellowship for 2018. Her main interests are in glycoanalytics, novel glycomics platform development and carbohydrate-mediated host-microbe interactions.
Affiliations and expertise
Lecturer in Glycosciences, National University of Ireland, Galway, Ireland

LJ

Lokesh Joshi

Prof. Lokesh Joshi is Director of the Advanced Glycoscience Research Cluster and leader of the Glycoscience Group at NUI Galway, a Co-Director of CÚRAM, a medical device centre, and the Vice-President for Research at NUI Galway. His principal focus of research is in understanding the roles of glycans and lectins in health and diseases and developing novel technologies for glycomics. Prof. Joshi has been involved in two spin out companies, Arizona Engineered Therapeutics (AzERx) and Aquila Biosciences. The NIH and VC sources funded AzERx to develop peptide-based therapeutics for vascular applications and AzERx was acquired by Orthologic (Now Capstone Therapeutics) in 2006. Aquila Bioscience is a healthcare company working on various projects funded by EI, EU, European Defence Agency and private industries. Prof. Joshi is an SFI-Stokes Professor of Glycosciences and the Irish representative on European Universities Association’s Research Programme Working group.
Affiliations and expertise
Director, Advanced Glycoscience Research Cluster and Leader, Glycoscience Group, NUI Galway, Ireland

View book on ScienceDirect

Read Translational Glycobiology in Human Health and Disease on ScienceDirect